SMPD1 and COVID-19: While amitriptyline has demonstrated potential antiviral mechanisms against SARS-CoV-2 in laboratory studies—primarily through the inhibition of acid sphingomyelinase and subsequent reduction of ceramide-mediated viral entry—there is currently insufficient clinical evidence to support its efficacy in treating COVID-19 patients.